Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million from $12.2 million in Q1 2024 [27] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [29] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][23] - Comp sales for mature clinics (open for at least 48 months) were down 2% [23] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25] Market Data and Key Metrics Changes - The company is experiencing a dynamic consumer environment, with consumer sentiment affecting new patient volumes [11][43] - The company anticipates system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [31] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][49] - The focus is on strengthening core operations, reigniting growth, and improving profitability through dynamic revenue management and enhanced digital marketing strategies [12][18] - The company plans to launch a new marketing campaign centered around pain relief in the second half of the year [36] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the impact of economic headwinds, inflation, and consumer sentiment on operations but remains optimistic about transitioning to a franchise model [33] - The company expects to see a transformative financial impact as corporate clinics transition to franchise royalties and fees, leading to increased profitability [33] Other Important Information - The company has welcomed new executives to enhance legal strategy and patient experience [39] - The Joint has been recognized as one of the fastest-growing franchises and ranked 37th in the Franchise 500 by Entrepreneur Magazine [40] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by consumer sentiment, but retention rates remain stable [42][44] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [45][47] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [49] Question: Comp sales performance and strategies for mature clinics - Comp sales for mature clinics have been consistent, and operational strategies will be geared towards strengthening these clinics [80][81] Question: Dynamic pricing impact - Management is exploring various pricing models and anticipates that pricing adjustments could significantly impact total system wide sales [60][62] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 as the transition to a single marketing agency is completed [66] Question: Cost of the franchisee spring convention - The cost of the convention was lower than previous years, impacting the sales and marketing line [75][76]

Financial Performance - Q1 2025 - Revenue from continuing operations increased by 7% to $131 million compared to $122 million in Q1 2024[33] - Cost of revenue increased by 10% to $30 million [33] - Sales and marketing expenses increased significantly by 57% to $35 million [33] - System-wide sales increased by 5% in Q1 2025 [29] - Comp sales increased by 3% in Q1 2025 [29] - Net loss from continuing operations was $(05) million [33] - Consolidated Adjusted EBITDA was $29 million [33] Liquidity and Cash Flow - Unrestricted cash was $219 million as of March 31 2025 [35] - The company has access to a $20 million line of credit through February 2027 [35, 37] - $37 million was used in operations during the quarter [38] 2025 Guidance - The company reiterates its 2025 guidance for system-wide sales between $550 million and $570 million [39] - The company anticipates mid-single-digit comp sales growth for clinics open 13 months or more [39] - Consolidated Adjusted EBITDA is expected to be between $100 million and $115 million [39]

The Joint Corp. Reports First Quarter 2025 Financial Results - Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 8, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended March 31, 2025. The results of operations of the corporate clinics business segment have been classified as discon ...

Core Insights - The Joint Corp. reported a 7% increase in revenue from continuing operations, reaching $13.1 million in Q1 2025 compared to $12.2 million in Q1 2024, driven by a greater number of franchised clinics [7][8] - System-wide sales increased by 5% to $132.6 million, indicating economic resilience [8] - The company experienced a net loss from continuing operations of $506,000, compared to a loss of $399,000 in the same quarter of the previous year [11] Financial Performance - Adjusted EBITDA for continuing operations was $46,394, down from $424,708 in Q1 2024 [12][37] - Selling and marketing expenses rose to $3.5 million from $2.2 million in Q1 2024, reflecting the costs associated with transitioning to a new marketing team [8][10] - The cost of revenue increased to $3.0 million from $2.7 million, attributed to higher regional developer royalties and commissions [7] Operational Highlights - The company sold 9 franchise licenses in Q1 2025, a decrease from 15 in Q1 2024, due to the refranchising process [9] - Five new franchised clinics were opened, while two corporate clinics were refranchised and one was closed, bringing the total clinic count to 969 [9] - The company aims to enhance its digital marketing and patient experience to drive growth in new clinic openings and system-wide sales [5] Guidance and Future Outlook - The company expects system-wide sales to be between $550 million and $570 million for 2025, compared to $530.3 million in 2024 [19] - Comp sales for clinics open for 13 months or more are projected to be in the mid-single digits, up from 4% in 2024 [19] - Consolidated Adjusted EBITDA is anticipated to be between $10.0 million and $11.5 million, compared to $11.4 million in 2024 [19]

OAKBROOK TERRACE, Illinois, and DENVER, May 08, 2025 (GLOBE NEWSWIRE) -- The Joint Commission and Palantir Technologies announced today a long-term strategic partnership aimed at revolutionizing how healthcare organization and accreditation data are gathered and utilized. This will support healthcare organizations in benchmarking quality and improving outcomes. By leveraging Palantir’s cutting-edge data analytics and artificial intelligence, this collaboration will allow both The Joint Commission and health ...

Investors in The Joint Corp. (JYNT) need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $7.50 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also ...

Core Insights - The Joint Corp. is strengthening its leadership team to enhance company core, reignite growth, and improve profitability [1] Leadership Appointments - Andra J. Terrell has been appointed as Senior Vice President Legal, bringing 20 years of experience in franchising legal matters, compliance strategy, and complex transactions [2][5] - Eric Wyatt has been appointed as Senior Vice President Operations and Patient Experience, with over 30 years of experience in franchise operations and general management [4][5] Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S., operating over 950 locations and achieving more than 14 million patient visits annually [7] - The company has been recognized in various rankings, including Franchise Times' "Top 400" and "Fast & Serious" lists, and was named "No. 1 in Chiropractic Services" by Entrepreneur [7] Business Structure - The Joint Corp. operates as a franchisor of clinics and provides management services to affiliated chiropractic practices in several states [8]

– How Chiropractic Care Can Help Ease Joint Pain and Improve Mobility –SCOTTSDALE, Ariz., May 2, 2025 /PRNewswire/ -- According to the CDC, arthritis affects more than 50 million Americans, and nearly 26 million of those with arthritis are unable to do everyday activities. The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, is encouraging patients to consider natural ways to support long-term joint health.Arthritis is one of the most ...

SCOTTSDALE, Ariz., May 1, 2025 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, has been named one of the 150 fastest-growing franchises by Entrepreneur magazine. The list identifies franchise brands with the greatest unit growth in North America over the last year, based on the data submitted for the most recent Franchise 500. The Joint ranks No. 37, and was also named to The 10+ Club, which honors brands that are wo ...

LAS VEGAS, April 30, 2025 (GLOBE NEWSWIRE) -- Jet.AI Inc. (“Jet.AI” or the “Company”) (Nasdaq: JTAI), a company transitioning to a pure-play artificial-intelligence (“AI”) data-center enterprise, announced the signing of a Letter of Intent (“LOI”) to form a joint venture (the “Joint Venture” or “JV”) with Consensus Core Technologies Inc. (“Consensus Core”), a Vancouver-based provider of high-performance GPU infrastructure and AI cloud services. The JV will pursue development of two hyperscale data-center ca ...